Clinical Trial

Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR)

Study acronym: KORR
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to see if people with knee osteoarthritis would be willing to comply and adhere to incorporating Recombinant Human Growth Hormone (rHGH), specifically Saizen Somatropin solution, into their treatment plan. Participants will be asked to: * Self-inject the treatment solution (placebo or somatropin) into the abdominal or gluteal area once per day for a total of 6 weeks. * Complete questionnaires related to their knee pain and activities of daily living. * Provide blood tests. * Complete various measurements including: circumference of thigh, calf, and abdomen; strength of thigh and knee; range of motion of both knees; and gait analysis.
Protocol Amendment History 1 change
critical Enrollment closed, study ongoing 2026-08-01
Trial Details
NCT Number NCT07036003
Lead Sponsor Dr. David Wasserstein
Collaborators: Sunnybrook Research Institute
Conditions Knee Osteoarthritis (Knee OA), Knee Osteoarthritis (OA)
Enrollment 34 participants
Start Date 2025-10-31
Primary Completion 2028-07 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-31